Coronary artery revascularization and the risk of death in men with prostate cancer - Abstract

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts.

 

We investigated whether the decrease in death from cardiovascular disease, a major competing risk, explains the observed increase in prostate cancer specific mortality before 1992.

Between 1991 and 2006, 1,880 men with known cardiovascular disease underwent radiation therapy for prostate cancer and were followed until July 2008. Cox regression multivariable analysis was performed to assess whether known prostate cancer prognostic factors, history of coronary artery revascularization for cardiovascular disease, age, Charlson comorbidity score and prostate cancer treatment were associated with the risk of death.

Despite a significantly higher Charlson comorbidity score (p < 0.001) due to a higher rate of prior myocardial infarction, the risk of death was significantly lower (adjusted hazard ratio 0.63, 95% CI 0.49-0.82, p < 0.001) in men who underwent revascularization. High grade prostate cancer contributed significantly to the risk of death in men who underwent revascularization (AHR 1.74, 95% CI 1.04-2.91, p = 0.04) but not in those who did not (AHR 1.18, 95% CI 0.88-1.58, p = 0.27).

The availability of and appropriate selection for revascularization may explain the increase in prostate cancer specific mortality before 1992. Men with cardiovascular disease in whom revascularization was not appropriate could consider active surveillance of prostate cancer because the increased risk of death was not associated with high grade prostate cancer.

Written by:
D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S, Ross R, Goldhaber SZ.   Are you the author?

Reference: J Urol. 2011 Sep;186(3):898-902.
doi: 10.1016/j.juro.2011.04.076

PubMed Abstract
PMID: 21788044

UroToday.com Prostate Cancer Section

 

 

email news signup